Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.05
AMED's Cash to Debt is ranked higher than
54% of the 306 Companies
in the Global Medical Care industry.

( Industry Median: 0.19 vs. AMED: 0.05 )
AMED' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 0.05

Equity to Asset 0.56
AMED's Equity to Asset is ranked higher than
83% of the 307 Companies
in the Global Medical Care industry.

( Industry Median: 0.41 vs. AMED: 0.56 )
AMED' s 10-Year Equity to Asset Range
Min: -0.31   Max: 1
Current: 0.56

-0.31
1
F-Score: 3
Z-Score: 3.40
M-Score: -2.02
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -0.09
AMED's Operating margin (%) is ranked higher than
59% of the 309 Companies
in the Global Medical Care industry.

( Industry Median: 8.52 vs. AMED: -0.09 )
AMED' s 10-Year Operating margin (%) Range
Min: -100.58   Max: 15.25
Current: -0.09

-100.58
15.25
Net-margin (%) -0.50
AMED's Net-margin (%) is ranked higher than
62% of the 309 Companies
in the Global Medical Care industry.

( Industry Median: 4.94 vs. AMED: -0.50 )
AMED' s 10-Year Net-margin (%) Range
Min: -97.66   Max: 9.33
Current: -0.5

-97.66
9.33
ROE (%) -1.60
AMED's ROE (%) is ranked higher than
61% of the 289 Companies
in the Global Medical Care industry.

( Industry Median: 10.03 vs. AMED: -1.60 )
AMED' s 10-Year ROE (%) Range
Min: -94.38   Max: 27.69
Current: -1.6

-94.38
27.69
ROA (%) -0.83
AMED's ROA (%) is ranked higher than
62% of the 310 Companies
in the Global Medical Care industry.

( Industry Median: 3.52 vs. AMED: -0.83 )
AMED' s 10-Year ROA (%) Range
Min: -73.91   Max: 14.03
Current: -0.83

-73.91
14.03
ROC (Joel Greenblatt) (%) -0.74
AMED's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 309 Companies
in the Global Medical Care industry.

( Industry Median: 18.24 vs. AMED: -0.74 )
AMED' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -483.95   Max: 387.62
Current: -0.74

-483.95
387.62
Revenue Growth (%) -10.70
AMED's Revenue Growth (%) is ranked higher than
53% of the 242 Companies
in the Global Medical Care industry.

( Industry Median: 7.10 vs. AMED: -10.70 )
AMED' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 35.1
Current: -10.7

0
35.1
» AMED's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

AMED Guru Trades in Q4 2013

Charles Brandes 215,640 sh (-5.9%)
» More
Q1 2014

AMED Guru Trades in Q1 2014

Jim Simons 144,680 sh (New)
Charles Brandes 165,125 sh (-23.43%)
» More
Q2 2014

AMED Guru Trades in Q2 2014

Jim Simons 338,601 sh (+134.03%)
Charles Brandes 165,290 sh (+0.1%)
» More
Q3 2014

AMED Guru Trades in Q3 2014

Steven Cohen 62,400 sh (New)
Paul Tudor Jones 13,000 sh (New)
Jim Simons 259,501 sh (-23.36%)
Charles Brandes 15,810 sh (-90.43%)
» More
» Details

Insider Trades

Latest Guru Trades with AMED

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2014-09-30 Reduce -90.43%0.03%$15.58 - $21.78 $ 27.6743%15810
Charles Brandes 2014-03-31 Reduce -23.43%0.01%$14.09 - $16.96 $ 27.6781%165125
Charles Brandes 2013-03-31 Add 515.74%0.03%$10.95 - $13.11 $ 27.67138%225885
Joel Greenblatt 2012-12-31 Sold Out 0.06%$9.65 - $13.56 $ 27.67144%0
Charles Brandes 2012-12-31 New Buy$9.65 - $13.56 $ 27.67144%36685
Joel Greenblatt 2012-09-30 Reduce -49.75%0.06%$11.3 - $15.84 $ 27.67103%65015
Charles Brandes 2012-09-30 Sold Out 0.0017%$11.3 - $15.84 $ 27.67103%0
John Hussman 2012-06-30 Sold Out 0.04%$9.87 - $15.03 $ 27.67123%0
Joel Greenblatt 2012-03-31 Add 98.71%0.09%$9.56 - $14.66 $ 27.67152%144813
Charles Brandes 2012-03-31 New Buy$9.56 - $14.66 $ 27.67152%20195
David Dreman 2011-12-31 Sold Out 0.5%$9.59 - $14.56 $ 27.67136%0
George Soros 2011-12-31 Sold Out 0.0041%$9.59 - $14.56 $ 27.67136%0
Charles Brandes 2011-12-31 Sold Out 0.0021%$9.59 - $14.56 $ 27.67136%0
Joel Greenblatt 2011-09-30 Add 125.99%0.09%$13.29 - $27.55 $ 27.6740%64379
George Soros 2011-09-30 Reduce -91.93%0.07%$13.29 - $27.55 $ 27.6740%16100
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.40
AMED's P/B is ranked higher than
78% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 2.93 vs. AMED: 2.40 )
AMED' s 10-Year P/B Range
Min: 0.5   Max: 6.34
Current: 2.4

0.5
6.34
P/S 0.70
AMED's P/S is ranked higher than
85% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 1.57 vs. AMED: 0.70 )
AMED' s 10-Year P/S Range
Min: 0.19   Max: 2.36
Current: 0.7

0.19
2.36
EV-to-EBIT -918.08
AMED's EV-to-EBIT is ranked lower than
56% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 24.30 vs. AMED: -918.08 )
AMED' s 10-Year EV-to-EBIT Range
Min: -905.3   Max: 18.9
Current: -918.08

-905.3
18.9
Current Ratio 0.75
AMED's Current Ratio is ranked higher than
58% of the 310 Companies
in the Global Medical Care industry.

( Industry Median: 1.32 vs. AMED: 0.75 )
AMED' s 10-Year Current Ratio Range
Min: 0.33   Max: 2.88
Current: 0.75

0.33
2.88
Quick Ratio 0.75
AMED's Quick Ratio is ranked higher than
59% of the 310 Companies
in the Global Medical Care industry.

( Industry Median: 1.19 vs. AMED: 0.75 )
AMED' s 10-Year Quick Ratio Range
Min: 0.31   Max: 2.85
Current: 0.75

0.31
2.85

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 6.50
AMED's Price/Tangible Book is ranked higher than
75% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 15.23 vs. AMED: 6.50 )
AMED' s 10-Year Price/Tangible Book Range
Min: 0.35   Max: 122.85
Current: 6.5

0.35
122.85
Price/DCF (Projected) 0.80
AMED's Price/DCF (Projected) is ranked higher than
94% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 4.02 vs. AMED: 0.80 )
AMED' s 10-Year Price/DCF (Projected) Range
Min: 0.16   Max: 12.84
Current: 0.8

0.16
12.84
Price/Median PS Value 0.80
AMED's Price/Median PS Value is ranked higher than
91% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 1.19 vs. AMED: 0.80 )
AMED' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 2.31
Current: 0.8

0.12
2.31
Price/Peter Lynch Fair Value 0.40
AMED's Price/Peter Lynch Fair Value is ranked lower than
56% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. AMED: 0.40 )
AMED' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.21   Max: 3.24
Current: 0.4

0.21
3.24
Earnings Yield (Greenblatt) -0.10
AMED's Earnings Yield (Greenblatt) is ranked higher than
58% of the 306 Companies
in the Global Medical Care industry.

( Industry Median: 4.60 vs. AMED: -0.10 )
AMED' s 10-Year Earnings Yield (Greenblatt) Range
Min: -0.1   Max: 33.7
Current: -0.1

-0.1
33.7
Forward Rate of Return (Yacktman) 41.28
AMED's Forward Rate of Return (Yacktman) is ranked higher than
96% of the 212 Companies
in the Global Medical Care industry.

( Industry Median: 12.92 vs. AMED: 41.28 )
AMED' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1.5   Max: 104.4
Current: 41.28

-1.5
104.4

Business Description

Industry: Health Care Providers » Medical Care
Compare:CHE, FMS, DVA, FSNUY, BDUUF » details
Traded in other countries:ADY.Germany,
Amedisys Inc was originally incorporated in Louisiana in 1982. Its operations were transferred to a Delaware corporation, which was incorporated in 1994; and became a publicly traded company in August of that year. The Company is a provider of low-cost home health services to the chronic, co-morbid, aging American population. The operations involve servicing patients through its two reportable business segments: home health and hospice. The home health segment delivers services in the homes of individuals who may be recovering from an illness, injury or surgery. Its hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. Individuals with a terminal illness such as heart disease, pulmonary disease, dementia, Alzheimers, HIV/AIDS or cancer may be eligible for hospice care. The Company operates 41 home health care centers and five hospice care centers with care centers servicing the same markets, sold 19 home health care centers and one hospice care center and closed 10 home health care centers. The Companys operations are regulated by Federal, state and local authorities.
» More Articles for AMED

Headlines

Articles On GuruFocus.com
comment on AMED Jun 20 2012 
well undervalued, st Jan 24 2012 
“Powerball” Ideas - Home Healthcare Companies: AFAM, GTIV, LHCG, AMED Jan 05 2012 
AMED: Investment Opportunity When the Price Hits an 8-Year Low Dec 27 2011 
Almost Family: The Magic Formula Stock is getting cheaper and cheaper Dec 11 2011 
guru bargain Oct 05 2011 
Magic Formula Stock: Amedisys (AMED) Aug 05 2011 
Home Healthcare: Heavily Shorted long Opportunity May 30 2011 
Amedisys Inc (AMED) CFO Dale E Redman buys 1,000 Shares Aug 25 2010 
Amedisys Inc Reports Operating Results (10-Q) Aug 09 2010 


More From Other Websites
Amedisys Board Names Paul B. Kusserow as New CEO Dec 16 2014
AMEDISYS INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... Dec 16 2014
8:33 am Amedisys named Paul Kusserow as President and Chief Executive Officer Dec 16 2014
Amedisys Board Names Paul B. Kusserow as New CEO Dec 16 2014
AMEDISYS INC Files SEC form 8-K, Regulation FD Disclosure Dec 10 2014
Amedisys to Present at the 25th Annual Oppenheimer Healthcare Conference Dec 10 2014
Amedisys to Present at the 25th Annual Oppenheimer Healthcare Conference Dec 10 2014
The Right Time to Invest in Amedisys (AMED)? Dec 09 2014
Amedisys upgraded by RBC Capital Mkts Dec 01 2014
Market Has Not Yet Noticed Potential in Amedisys (AMED); Have You? Nov 28 2014
Amedisys Inc. (AMED): Strong Industry, Solid Earnings Estimate Revisions Nov 21 2014
2014 HomeCare Elite Recognizes Top Amedisys Care Teams Nationwide Nov 05 2014
2014 HomeCare Elite Recognizes Top Amedisys Care Teams Nationwide Nov 05 2014
Can Amedisys (AMED) Run Higher on Strong Earnings Estimate Revisions? Nov 05 2014
10-Q for Amedisys, Inc. Oct 31 2014
Amedysis Turns Around with Q3 Earnings Beat, Shares Rally Oct 31 2014
Amedisys Inc. (AMED) in Focus: Stock Surges 15.9% Oct 30 2014
FOMC: Not necessarily more “hawkish”, but certainly appeared a bit “less dovish” Oct 29 2014
Amedisys quarterly profit beats as expenses fall Oct 29 2014
Amedisys beats Street 3Q forecasts Oct 29 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK